Abstract

Atherosclerosis and its associated complications represent major causes of morbidity and mortality in the industrialized or Western countries. Monocyte chemoattractant protein-1 (MCP-1) is critical for the initiating and developing of atherosclerotic lesions. Interleukin-8 (IL-8), a CXC chemokine, stimulates neutrophil chemotaxis. Ticlopidine is one of the antiplatelet drugs used to prevent thrombus formation relevant to the pathophysiology of atherothrombosis. In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF--stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Ticlopidine declined U937 cells adhesion and chemotaxis as compared to TNF-stimulated alone. Furthermore, the inhibitory effects were neither due to decreased HUVEC viability, nor through NF-kB inhibition. These results suggest that ticlopidine decreased TNF-induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion. Therefore, the data provide additional therapeutic machinery of ticlopidine in treatment and prevention of atherosclerosis.

Original languageEnglish
Article number917837
JournalJournal of Biomedicine and Biotechnology
Volume2009
DOIs
Publication statusPublished - 2009

Fingerprint

Ticlopidine
Chemokine CCL2
Endothelial cells
Human Umbilical Vein Endothelial Cells
Interleukin-8
Vascular Cell Adhesion Molecule-1
Chemotaxis
Cell Adhesion
Atherosclerosis
CXC Chemokines
U937 Cells
NF-kappa B
Platelet Aggregation Inhibitors
Cell adhesion
Machinery
Monocytes
Cell Survival
Neutrophils
Thrombosis
Adhesion

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Genetics
  • Molecular Biology
  • Health, Toxicology and Mutagenesis
  • Medicine(all)

Cite this

Reduction of monocyte chemoattractant protein-1 and interleukin-8 levels by ticlopidine in TNF-α stimulated human umbilical vein endothelial cells. / Hu, Chaur Jong; Lee, Yueh Lun; Shih, Neng Yao; Yang, Yi Yuan; Charoenfuprasert, Suparat; Dai, Yu Shan; Chang, Su Mei; Tsai, Yu-Hui; Tseng, How; Liu, Chia Yu; Leu, Sy Jye.

In: Journal of Biomedicine and Biotechnology, Vol. 2009, 917837, 2009.

Research output: Contribution to journalArticle

@article{50b58f721c3345c19a8572ba00cbe282,
title = "Reduction of monocyte chemoattractant protein-1 and interleukin-8 levels by ticlopidine in TNF-α stimulated human umbilical vein endothelial cells",
abstract = "Atherosclerosis and its associated complications represent major causes of morbidity and mortality in the industrialized or Western countries. Monocyte chemoattractant protein-1 (MCP-1) is critical for the initiating and developing of atherosclerotic lesions. Interleukin-8 (IL-8), a CXC chemokine, stimulates neutrophil chemotaxis. Ticlopidine is one of the antiplatelet drugs used to prevent thrombus formation relevant to the pathophysiology of atherothrombosis. In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF--stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Ticlopidine declined U937 cells adhesion and chemotaxis as compared to TNF-stimulated alone. Furthermore, the inhibitory effects were neither due to decreased HUVEC viability, nor through NF-kB inhibition. These results suggest that ticlopidine decreased TNF-induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion. Therefore, the data provide additional therapeutic machinery of ticlopidine in treatment and prevention of atherosclerosis.",
author = "Hu, {Chaur Jong} and Lee, {Yueh Lun} and Shih, {Neng Yao} and Yang, {Yi Yuan} and Suparat Charoenfuprasert and Dai, {Yu Shan} and Chang, {Su Mei} and Yu-Hui Tsai and How Tseng and Liu, {Chia Yu} and Leu, {Sy Jye}",
year = "2009",
doi = "10.1155/2009/917837",
language = "English",
volume = "2009",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Reduction of monocyte chemoattractant protein-1 and interleukin-8 levels by ticlopidine in TNF-α stimulated human umbilical vein endothelial cells

AU - Hu, Chaur Jong

AU - Lee, Yueh Lun

AU - Shih, Neng Yao

AU - Yang, Yi Yuan

AU - Charoenfuprasert, Suparat

AU - Dai, Yu Shan

AU - Chang, Su Mei

AU - Tsai, Yu-Hui

AU - Tseng, How

AU - Liu, Chia Yu

AU - Leu, Sy Jye

PY - 2009

Y1 - 2009

N2 - Atherosclerosis and its associated complications represent major causes of morbidity and mortality in the industrialized or Western countries. Monocyte chemoattractant protein-1 (MCP-1) is critical for the initiating and developing of atherosclerotic lesions. Interleukin-8 (IL-8), a CXC chemokine, stimulates neutrophil chemotaxis. Ticlopidine is one of the antiplatelet drugs used to prevent thrombus formation relevant to the pathophysiology of atherothrombosis. In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF--stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Ticlopidine declined U937 cells adhesion and chemotaxis as compared to TNF-stimulated alone. Furthermore, the inhibitory effects were neither due to decreased HUVEC viability, nor through NF-kB inhibition. These results suggest that ticlopidine decreased TNF-induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion. Therefore, the data provide additional therapeutic machinery of ticlopidine in treatment and prevention of atherosclerosis.

AB - Atherosclerosis and its associated complications represent major causes of morbidity and mortality in the industrialized or Western countries. Monocyte chemoattractant protein-1 (MCP-1) is critical for the initiating and developing of atherosclerotic lesions. Interleukin-8 (IL-8), a CXC chemokine, stimulates neutrophil chemotaxis. Ticlopidine is one of the antiplatelet drugs used to prevent thrombus formation relevant to the pathophysiology of atherothrombosis. In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF--stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Ticlopidine declined U937 cells adhesion and chemotaxis as compared to TNF-stimulated alone. Furthermore, the inhibitory effects were neither due to decreased HUVEC viability, nor through NF-kB inhibition. These results suggest that ticlopidine decreased TNF-induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion. Therefore, the data provide additional therapeutic machinery of ticlopidine in treatment and prevention of atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=75149190143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149190143&partnerID=8YFLogxK

U2 - 10.1155/2009/917837

DO - 10.1155/2009/917837

M3 - Article

C2 - 20069129

AN - SCOPUS:75149190143

VL - 2009

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 917837

ER -